Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vadadustat for ESA-hyporesponsive anemia in DD-CKD
NCT03140722Phase 2Terminated
- Sponsor
- Akebia Therapeutics
- Start
- May 2017
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vadadustat in anemia of chronic kidney disease (CKD-A), sponsored by Akebia Therapeutics. Started May 2017; status: terminated.
02
Drugs
vadadustat
03
Conditions
anemia of chronic kidney disease (CKD-A)
Beyond the preview
Go deeper on NCT03140722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03140722.